CA
NZ
UK
AU
IND
US
…
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. was founded in 2005 and is based in Flemington, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Publicly available information on Arno Therapeutics (OTC: ARNI) is limited and the company has few recent SEC filings or official disclosures, so its core business and development stage are not clearly documented. Because of sparse disclosure, clear long-term growth drivers cannot be identified, though the stock may attract investors seeking speculative, low-liquidity OTC opportunities.
Material risks include lack of transparency and up-to-date financial reporting, thin liquidity, potential for significant dilution, and absence of verifiable operational progress; investors should monitor company disclosures and filings.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
| Income before tax | -11.51M | 7.77M | -39.66M | -14.39M |
| Net income | -11.51M | 7.77M | -39.66M | -14.39M |
| Selling general administrative | 4.76M | 6.25M | 3.46M | 2.30M |
| Gross profit | 0.00M | 0.00M | 0.00M | 0.00M |
| Ebit | -13.41M | -21.09M | -16.94M | -10.84M |
| Operating income | -13.41M | -21.09M | -16.94M | -10.84M |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.00M |
| Income tax expense | 0.00M | 0.00M | 0.00M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 13.41M | 21.09M | 16.94M | 10.84M |
| Cost of revenue | 0.00M | 0.00M | 0.00M | 0.00M |
| Total other income expense net | 1.90M | 28.86M | -22.72M | -3.55M |
| Net income from continuing ops | -11.51M | 7.77M | -39.66M | -14.39M |
| Net income applicable to common shares | -11.51M | 7.77M | -39.66M | -14.39M |
| Breakdown | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
| Total assets | 0.36M | 8.25M | 26.88M | 12.89M |
| Other current assets | 0.26M | 0.26M | 0.09M | 0.20M |
| Total liab | 8.99M | 5.29M | 39.40M | 24.26M |
| Total stockholder equity | -8.62M | -0.59M | -12.88M | -12.27M |
| Deferred long term liab | - | - | - | 1.71M |
| Other current liab | 0.00M | 0.00M | 0.01M | 0.61M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -93.29M | -81.79M | -89.56M | -49.90M |
| Other liab | 4.75M | 3.12M | 35.50M | 20.52M |
| Other assets | 0.01M | 0.01M | 0.01M | 1.72M |
| Cash | 0.07M | 7.95M | 26.77M | 10.94M |
| Total current liabilities | 4.23M | 2.16M | 3.90M | 3.25M |
| Short term debt | 2.10M | 0.01M | - | 0.49M |
| Short long term debt | 2.10M | 0.01M | - | 0.49M |
| Property plant equipment | 0.02M | 0.03M | 0.01M | 0.02M |
| Total current assets | 0.33M | 8.21M | 26.86M | 11.15M |
| Net tangible assets | -8.62M | -0.59M | -12.88M | -12.27M |
| Long term debt | 0.00M | 0.01M | 35.86M | 0.49M |
| Accounts payable | 1.01M | 0.74M | 2.94M | 1.55M |
| Breakdown | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
| Change to liabilities | 0.27M | -2.20M | 1.39M | 0.87M |
| Total cashflows from investing activities | - | -0.02M | -0.02M | -0.02M |
| Net borrowings | 2.10M | -0.00M | -0.00M | 14.86M |
| Total cash from financing activities | 2.08M | -0.00M | 30.07M | 13.68M |
| Change to operating activities | -0.29M | 0.28M | -0.61M | -0.09M |
| Net income | -11.51M | 7.77M | -39.66M | -14.39M |
| Change in cash | -7.88M | -18.83M | 15.83M | 4.27M |
| Total cash from operating activities | -9.97M | -18.81M | -14.24M | -9.42M |
| Depreciation | 0.01M | 0.01M | 0.01M | 0.01M |
| Sale purchase of stock | - | - | 19.43M | 19.43M |
| Other cashflows from financing activities | -0.01M | -0.01M | 10.65M | -1.17M |
| Change to netincome | 1.55M | -24.67M | 24.62M | 4.18M |
| Capital expenditures | 0.00M | 0.02M | 0.02M | 0.02M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ARNI Arno Therapeutics |
- -% |
0.00 | - | - | - | - | 0.14 |
| NVO Novo Nordisk A/S |
0.80 2.03% |
39.94 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
19.54 3.62% |
559.54 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
93.31 11.40% |
912.08 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. was founded in 2005 and is based in Flemington, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. David M. Tanen J.D. | Sec. | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.89%
Communication Services
-0.40%
Consumer Cyclical
-0.22%
Consumer Defensive
+0.33%
Energy
-0.12%
Financial Services
-0.79%
Financials
+2.35%
Healthcare
-1.57%
Industrials
-1.00%
Real Estate
-0.28%
Technology
-3.22%
Utilities
-0.27%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...